Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sektionen
Studienregister
Sie sind hier: Startseite / Klinische Studien / Studienregister

Studienregister

  • Akute Leukämien (Beschreibung)
  • Allogene Stammzelltransplantation (Beschreibung)
    • Graft-versus-Host-Reaktion (GvHD) (Beschreibung)
      • akute GvHD
        • CSL964_2001_MODULAATE Study (bei GvHD): A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study)
        • GRAVITAS-301 Studie (INCB39110-301): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
        • HERACLES: Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota tranSfer
        • JZP963-201: A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem CellTransplant
      • chronische GvHD
      • Prophylaxe
    • Primärtherapie
      • CSL964_2001_MODULAATE Study (bei GvHD): A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study)
    • Rezidivtherapie
      • AZALENA 2013: Phase-II trial to assess the efficacy and safety of Lenalidomide in addition to 5-Azacitidine and donor lymphocyte infusions (DLI) for the treatment of patients with MDS, CMML or AML who relapse after allogeneic stem cell transplantation.
  • Chronische lymphatische Leukämien (Beschreibung)
    • Primärtherapie (Beschreibung)
      • CLL12: A placebo-controlled, double-blind, randomized, multicenter, three arm phase III study to compare the efficacy and safety of ibrutinib vs placebo in previously untreated early Binet stage A CLL patients with risk of early disease progression
      • CLL13: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation
      • CLLM1: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy
    • Rezidivtherapie (Beschreibung)
      • BGB 3111-305: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
      • CLL2-BAAG: A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustin followed by GA101 (Obinutuzumab), Acalabrutinib (ACP-196) and ABT-199 (Venetoclax) in patients with relapsed/refractory CLL (CLL2-BAAG-trial of the GCLLSG)
      • MB-CART2019.1 Lymphoma: A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant CD20 and CD19 positive B-NHL
      • MK-3475-170: A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
    • Große granuläre Lymphozyten-Leukämie (Beschreibung)
      • MK-3475-170: A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
  • Chronisch myeloproliferative Syndrome (Beschreibung)
  • Hodgkin Lymphome (Beschreibung)
  • Non-Hodgkin Lymphome (Beschreibung)
  • Myelodysplastische Syndrome (Beschreibung)
  • Post-Transplantationslymphoproliferative Erkrankungen (PTLD) (Beschreibung)
  • Sonstige Erkrankungen im Bereich Hämato-Onkologie (Beschreibung)
  • Solide Tumoren (Beschreibung)
  • CAR-T-Zell-Therapie (Beschreibung)
    • CCTL019E2202 Elara: A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
    • CCTL019H2301 - BELINDA: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
    • CCTL019J2101 - Portia: Phase Ib study of tisagenlecleucel in combination with pembrolizumab in relapsed/refractory (r/r) Diffuse Large Bcell Lymphoma (DLBCL) patients
    • JCAR017-BCM-001: A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma
    • JCAR017 GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells
    • KarMMa-3 (BB2121-MM-003): A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
    • MB-CART2019.1 Lymphoma: A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant CD20 and CD19 positive B-NHL
    • MB-CART20.1 Lymphoma: A phase I/II safety, dose finding and feasibility trial of MB-CART20.1 in patients with relapsed or resistant CD20 positive B-NHL
    • MB-CART20.1 Melanoma: Multicenter phase I trial of MB-CART20.1 for the treatment of patients with metastatic melanoma
  • Bewegung und Krebs (Beschreibung)
  • Infektiologie (Beschreibung)
  • Tuberkulose (Beschreibung)
  • Immunologie (Beschreibung)
  • Sonstige